Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand.
Animal, Antibodies-Monoclonal: tu, Chimera, DNA: an, Graft-Rejection: pc, Graft-Survival: im, Hematopoietic-Stem-Cells: ph, Immune-Tolerance: im, Lymph-Nodes, Male, Membrane-Glycoproteins: im, Mice, Mice-Inbred-BALB-C, Mice-Inbred-CBA, Mice-Inbred-C57BL, Polymerase-Chain-Reaction, Skin-Transplantation: im, Spleen: cy, SUPPORT-NON-U-S-GOVT, SUPPORT-U-S-GOVT-P-H-S
Transplantation 1997 Jul 27;64(2):329-35
DK25306/DK/NIDDK, DK41235/DK/NIDDK, DK36024/DK/NIDDK
Combined treatment with antibody against CD40 ligand and one transfusion of donor splenocytes prolonged survival of fully mismatched BALB/c skin allografts on C57BL/6 recipients, with approximately 20% of grafts surviving > 100 days. In vitro alloresponsiveness in treated animals was reduced in the immediate post-transplantation period, but by day 100 was increased despite the presence of a successful allograft. The presence of alloreactivity on day 100 was confirmed in vivo by adoptive transfer, which suggests that our protocol had induced either a state of split tolerance or graft accommodation. Mice with skin grafts that had survived for > or = 100 days revealed no evidence of lymphoid chimerism. Treatment with donor splenocytes and antibody against CD40 ligand permits long-term survival of highly antigenic donor skin allografts despite the presence of functionally intact alloreactive lymphocytes.
Markees, T G.; Phillips, N E.; Noelle, R J.; Shultz, L D.; Mordes, J P.; Greiner, D L.; and Rossini, A A., " Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand." (1997). Faculty Research 1990 - 1999. 882.